Login
$INBX
$77.66 -$5.64 (6.77%) Live

Company Executives

Officer Age In this role 2025 pay Source
Mark P. Lappe Also a director
Chief Executive Officer and Chairman of the Board of Directors
59 Not stated $2,892,473
Kelly D. Deck
Chief Financial Officer
46 Since 2024
2 years
$923,696
David J. Matly
President
40 Since 2025
1 year
$1,435,940

Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.

Directors
5
serving now
Independent
4 of 5
stated in the proxy
Director Independent Committees 2025 pay Source
Mark P. Lappe
Not independent None stated Paid as CEO
Douglas G. Forsyth
Independent
Compensation Committee
$202,685
Kimberly Manhard
Independent
Compensation Committee Nominating and Corporate Governance Committee
$183,685
Jon Faiz Kayyem, Ph.D.
Independent
Audit Committee
$192,185
Kristiina Vuori, M.D., Ph.D.
Independent
Audit Committee Nominating and Corporate Governance Committee
$186,185

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

5 disclosed in the proxy filed Apr 23, 2026
Former Parent
former parent that retained an equity interest in the Company of 8% upon the Distribution
Amount not stated

Transition Services Agreement under which the Company provided transition services to the Former Parent and other Sanofi entities following the Separation

With the Company Open in proxy
Former Parent
former parent that retained an equity interest in the Company of 8% upon the Distribution
$1.0 million
2024

Former Parent reimbursed the Company for severance payments made to former employees under the Transition Services Agreement

With the Company Open in proxy
Former Parent
former parent that retained an equity interest in the Company of 8% upon the Distribution
Amount not stated

Pharmacovigilance Agreement entered into with the Former Parent for sharing information for regulatory and pharmacovigilance compliance

With the Company Open in proxy
Brendan P. Eckelman, Ph.D.
former Chief Scientific Officer of the Company; founder, chief executive officer and beneficial owner of significant equity interests in Scithera
$1.3 million
2025

License and Assignment Agreement licensing Company antibody library assets to Scithera for an up-front payment, milestone payments and royalties, and a Materials and Know-How Transfer Agreement

With Scithera, Inc. Open in proxy
directors and officers of the Company
directors and officers of the Company
Amount not stated

Indemnification agreements requiring the Company to indemnify each director and executive officer to the fullest extent permitted by law and the Certificate of Incorporation and Bylaws

With the Company Open in proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support